Rethinking checkpoint blockade for cancer treatment

Funded by the European Union’s Horizon Europe Innovation Council.
2022 Pathfinder Open program.

This project has received funding from the European Union’s Horizon Europe research and innovation programme under grant agreement number 101098965. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Innovation Council and SMEs Executive Agency (EISMEA). Neither the European Union nor the granting authority can be held responsible for them

Latest news and events

No news yet

Our motivation

REPRESSIT will generate a technology platform for off-the-shelf RIPR molecules (Receptor Inhibition by Phosphatase Recruitment) targeting any tyrosine phosphatase carrying inhibitory immune receptor.

The REPRESSIT consortium will create a Proof-of-Concept for full in vivo functionality of RIPR molecules against diverse T and NK cell receptors in preclinical tumor models.

Our expected outcomes will provide the foundation for our long-term vision of novel immune checkpoint therapeutics with unprecedented efficacy for more cancer patients.

Partners

This project brings together a range of research disciplines, including tumor immunologists, protein engineering experts, biochemists, biophysicists, and mass spectrometry specialists.  

Reach us!

You can talk to us using contact@repressit.eu or you can reach out any of our main researchers.

Selected publications